Option Care Health, Inc. OPCH
We take great care to ensure that the data presented and summarized in this overview for Option Care Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPCH
View all-
Black Rock Inc. New York, NY21MShares$599 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA18MShares$514 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA13.3MShares$380 Million0.08% of portfolio
-
Durable Capital Partners LP Bethesda, MD8.24MShares$235 Million2.1% of portfolio
-
State Street Corp Boston, MA6.18MShares$176 Million0.01% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA4.6MShares$131 Million0.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.14MShares$118 Million0.75% of portfolio
-
Geode Capital Management, LLC Boston, MA4.11MShares$117 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.56MShares$101 Million0.03% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.41MShares$97.2 Million0.08% of portfolio
Latest Institutional Activity in OPCH
Top Purchases
Top Sells
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Insider Transactions at OPCH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2025
|
Nicole Maggio Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,167
+21.3%
|
-
|
|
May 19
2025
|
Collin Smyser GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,713
-11.94%
|
$353,529
$33.09 P/Share
|
|
May 19
2025
|
Collin Smyser GC & Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
11,196
+5.69%
|
-
|
|
May 14
2025
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+29.4%
|
-
|
|
May 14
2025
|
Timothy P Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,415
+13.33%
|
$126,225
$15.9 P/Share
|
|
May 14
2025
|
R Carter Pate Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+10.9%
|
-
|
|
May 14
2025
|
Harry M Jansen Kraemer Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+1.9%
|
$195,840
$15.9 P/Share
|
|
May 14
2025
|
David W Golding Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,415
+3.57%
|
$126,225
$15.9 P/Share
|
|
May 14
2025
|
Natasha Deckmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,661
+10.85%
|
$84,915
$15.9 P/Share
|
|
May 14
2025
|
Elizabeth D Bierbower Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+17.41%
|
-
|
|
May 14
2025
|
Elizabeth Quadros Betten Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+16.03%
|
-
|
|
May 14
2025
|
Eric Brandt Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+32.7%
|
-
|
|
May 14
2025
|
Norman L. Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+29.4%
|
-
|
|
Apr 22
2025
|
Femi Adewunmi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,396
-6.93%
|
$43,276
$31.54 P/Share
|
|
Feb 28
2025
|
Michael Bavaro Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
30,996
-40.8%
|
$1,022,868
$33.26 P/Share
|
|
Feb 28
2025
|
Michael Bavaro Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,739
+4.74%
|
$353,736
$24.39 P/Share
|
|
Feb 24
2025
|
Femi Adewunmi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,287
+33.79%
|
-
|
|
Feb 24
2025
|
John Charles Rademacher Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,814
+9.05%
|
-
|
|
Feb 24
2025
|
Nicole Maggio Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,892
+23.38%
|
-
|
|
Feb 24
2025
|
Luke Whitworth Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,173
+15.32%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 562K shares |
|---|---|
| Open market or private purchase | 43K shares |
| Exercise of conversion of derivative security | 118K shares |
| Bona fide gift | 67.3K shares |
|---|---|
| Open market or private sale | 156K shares |
| Payment of exercise price or tax liability | 211K shares |